Cardiovascular safety of sulfonylureas: a meta‐analysis of randomized clinical trials

ConclusionsIn type 2 diabetes, the use of sulfonylureas is associated with increased mortality and a higher risk of stroke, whereas the overall incidence of MACE appears to be unaffected. Significant differences in cardiovascular risk could be present in direct comparisons with specific classes of glucose‐lowering agents, such as DPP4 inhibitors, but this hypothesis needs to be confirmed in long‐term cardiovascular outcomes trials. The results of this meta‐analysis need to be interpreted with caution, mainly because of limitations in trial quality and under‐reporting of information on cardiovascular events and mortality. However, the cardiovascular safety of sulfonylureas cannot be considered established unless it is evaluated in long‐term cardiovascular outcomes trials.
Source: Diabetes, Obesity and Metabolism - Category: Endocrinology Authors: Tags: ORIGINAL ARTICLE Source Type: research